These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 2532456)

  • 1. Evolving role of angiotensin-converting enzyme inhibitors in cardiovascular therapy. Second International Symposium on Cilazapril. February 9 to 11, 1989, Basel, Switzerland. Proceedings.
    Am J Med; 1989 Dec; 87(6B):1S-99S. PubMed ID: 2532456
    [No Abstract]   [Full Text] [Related]  

  • 2. First International Symposium on Cilazapril Preclinical and Clinical Pharmacology. Lausanne, switzerland, May 5-7, 1988. Proceedings.
    Brunner HR
    Br J Clin Pharmacol; 1989; 27 Suppl 2(Suppl 2):131S-328S. PubMed ID: 2527527
    [No Abstract]   [Full Text] [Related]  

  • 3. [New, in Austria registered specialty drugs. Inhibace (cilazapril)].
    Töglhofer W
    Wien Klin Wochenschr; 1992; 104(6):178-82. PubMed ID: 1533738
    [No Abstract]   [Full Text] [Related]  

  • 4. [Cilazapril in essential hypertension. A study of one year of continuous treatment].
    Lange H; Belz GG; Tschollar W; Wolf GK
    Med Klin (Munich); 1988 Sep; 83(17):554-8. PubMed ID: 2971866
    [No Abstract]   [Full Text] [Related]  

  • 5. Delaying disease.
    Br J Hosp Med; 1991 Nov; 46(5):345. PubMed ID: 1835663
    [No Abstract]   [Full Text] [Related]  

  • 6. Vascular angiotensin converting enzyme activity in spontaneously hypertensive rats and its inhibition with cilazapril.
    Nakamura Y; Nakamura K; Matsukura T; Nakamura K
    J Hypertens; 1988 Feb; 6(2):105-10. PubMed ID: 2832472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Progress in new cardiovascular treatment. Background discussion and interview in the Basel Roche Research Center].
    Keil U
    Fortschr Med; 1996 Feb; 114(4):39-40. PubMed ID: 8852686
    [No Abstract]   [Full Text] [Related]  

  • 8. Anti-ischemic effects of cilazapril in patients with both hypertension and angina pectoris. Preliminary report of a pilot study.
    Schneeweiss A; Marmor AT; Rettig-Stürmer G
    Cardiology; 1991; 79(1):46-8. PubMed ID: 1838032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin-converting enzyme inhibitors for the prevention and treatment of cardiovascular disease.
    Frishman WH
    Heart Dis; 2000; 2(3):183-4. PubMed ID: 11794142
    [No Abstract]   [Full Text] [Related]  

  • 10. [Cardioprotection through ACE inhibition. Satellite symposium of the 12th scientific meeting of the International Society of Hypertension. 26 May 1988, Kyoto, Japan].
    Fortschr Med Suppl; 1988; 51():1-17. PubMed ID: 2904397
    [No Abstract]   [Full Text] [Related]  

  • 11. Cardiovascular remodeling and its correction: toward a comprehensive strategy.
    Bühler FR; Laragh JH; Holzgreve H
    Am J Med; 1993 Apr; 94(4A):1S-3S. PubMed ID: 8488850
    [No Abstract]   [Full Text] [Related]  

  • 12. Kinin and angiotensin II receptor antagonists in rats with chronic renal failure: chronic effects on cardio- and renoprotection of angiotensin converting enzyme inhibitors.
    Kohzuki M; Kanazawa M; Liu PF; Kamimoto M; Yoshida K; Saito T; Yasujima M; Sato T; Abe K
    J Hypertens; 1995 Dec; 13(12 Pt 2):1785-90. PubMed ID: 8903652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectively targetting the renin-angiotensin-aldosterone system in cardiovascular and renal disease: rationale for using angiotensin II receptor blockers in combination with angiotensin-converting enzyme inhibitors.
    Weinberg MS; Weinberg AJ; Zappe DH
    J Renin Angiotensin Aldosterone Syst; 2000 Sep; 1(3):217-33. PubMed ID: 11881029
    [No Abstract]   [Full Text] [Related]  

  • 14. Calcium antagonists in cardiovascular disease: rationale for 24-hour action. Proceedings of an official satellite symposium and papers on amlodipine presented at the 25th Anniversary International Symposium on Calcium Antagonists in Hypertension. Basel, Switzerland, February 11-12, 1988.
    J Cardiovasc Pharmacol; 1988; 12 Suppl 7():S1-114. PubMed ID: 2467114
    [No Abstract]   [Full Text] [Related]  

  • 15. Glucose tolerance and insulin secretion in essential hypertension after treatment with an angiotensin converting enzyme inhibitor.
    Santoro D; Natali A; Galvan AQ; Masoni A; Gazzetti P; Ferrannini E
    J Hypertens Suppl; 1991 Dec; 9(6):S406-7. PubMed ID: 1840204
    [No Abstract]   [Full Text] [Related]  

  • 16. Angiotensin converting enzyme inhibition in the 1990s. A symposium of the First International Symposium on Angiotensin Converting Enzyme Inhibition. 14 February 1989, London, UK. Proceedings.
    J Hypertens Suppl; 1989 Sep; 7(5):S1-40. PubMed ID: 2809811
    [No Abstract]   [Full Text] [Related]  

  • 17. Endothelin-converting enzyme inhibitors: their application in cardiovascular diseases.
    Cerdeira AS; Brás-Silva C; Leite-Moreira AF
    Rev Port Cardiol; 2008 Mar; 27(3):385-408. PubMed ID: 18551924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolongation of life with angiotensin converting enzyme inhibitor therapy.
    Torp-Pedersen C; Køber L
    Eur Heart J; 2000 Apr; 21(8):597-8. PubMed ID: 10731392
    [No Abstract]   [Full Text] [Related]  

  • 19. Angiotensin converting enzyme inhibition: changing the course of cardiovascular disease. Proceedings of an international symposium. 22-24 October 1993, Barcelona, Spain.
    J Hypertens Suppl; 1994 Jul; 12(4):S1-104. PubMed ID: 7965268
    [No Abstract]   [Full Text] [Related]  

  • 20. The place of angiotensin-converting enzyme inhibition in the treatment of cardiovascular diseases.
    Gavras H
    N Engl J Med; 1988 Dec; 319(23):1541-3. PubMed ID: 3185679
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.